Molecular mechanism of progression to castration resistant prostate cancer and its application for tailor made treatment
Project/Area Number |
25462503
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Urology
|
Research Institution | Toho University |
Principal Investigator |
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Keywords | 前立腺癌 / 去勢抵抗性前立腺癌 / ERG / 予後予測モデル / PET / ドセタキセル / 酢酸アビラテロン / アンチアンドロゲン / アンドロゲン受容体 / 予測モデル / アビラテロン / PTEN / ホルモン療法 |
Outline of Final Research Achievements |
To investigate the association of ERG expression, one of the most important molecular mechanism of progression to castration resistant prostate cancer (CRPC), with other molecular abnormalities, we examined specimens from radical prostatectomy, prostate biopsy, trans-urethral resection and autopsy. We examined the potential association of ERG expression and other gene abnormalities and clinical factors and found that ERG expression plays an important role of progression of CRPC. Especially, ERG expression was strongly related to PTEN expression. Also, we examined prognostic factors for efficacy of each CRPC drugs and made statistical prognostic models (nomograms). We have developed novel PET diagnostic drug reconizing amino acid tranportor and we attended the first global advanced prostate cancer conference held at St. Gallen, Switzland as a consensus panel member and debated about these new findings and other future CRPC treatment.
|
Report
(3 results)
Research Products
(34 results)
-
-
-
-
-
[Journal Article] Diagnostic performance and safety of NMK36 (trans-1-Amino-3-[18F] fluorocyclobutanecarboxylic acid)-PET/CT in primary prostate cancer: Multicenter phase IIb clinical trial.2016
Author(s)
Suzuki H, Inoue Y, Fujimoto H, Yonase J, Tanabe K, Fukasawa S, Inoue T, Saito S, Ueno M, Otaka A, Murakami K, Ishihara K, Kaji Y, Kuroki Y, Koizumi K, Yoshimura M, Takahashi H
-
Journal Title
Jpn J Clin Oncol
Volume: 46
Issue: 2
Pages: 152-162
DOI
Related Report
Peer Reviewed / Open Access
-
-
[Journal Article] Management of patients with advanced prostate cancer: Recommendations of the St.Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.2015
Author(s)
Gillessen S, Omlin A, Attard G, de Bono JS, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza H, Beer TM, Beltran H, Chinnaiyan AM, Daugaard G, Davis ID, De Santis M, Olmos D, Padhani AR, Parker C, Rubin MA, Schalken JA, Scher HI, Sella A, Shore ND, Small EJ, Sternberg CN, Suzuki H, Sweeney CJ, Tannock IF, Tombal B
-
Journal Title
Ann Oncol
Volume: 26
Issue: 8
Pages: 1589-1604
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research / Acknowledgement Compliant
-
[Journal Article] External validation and comparison of two nomograms predicting the probability of Gleason sum upgrading between biopsy and radical prostatectomy pathology in two patient populations: a retrospective cohort study.2015
Author(s)
Utsumi T, Oka R, Endo T, Yano M, Kamijima S, Kamiya N, Fujimura M, Sekita N, Mikami K, Hiruta N,Suzuki H
-
Journal Title
Jpn J Clin Oncol
Volume: 45
Issue: 11
Pages: 1091-1095
DOI
Related Report
-
[Journal Article] Nadir Testosterone after Long-Term Followup Predicts Prognosis in Patients with Prostate Cancer Treated with Combined Androgen Blockade.2015
Author(s)
Kamada S, Sakamoto S, Ando K, Muroi A, Fuse M, Kawamura K, Imamoto T, Suzuki H, Nagata M, Nihei N, Akakura K, Ichikawa T.
-
Journal Title
Journal of Urology
Volume: 194
Issue: 5
Pages: 1264-70
DOI
Related Report
Peer Reviewed / Int'l Joint Research / Acknowledgement Compliant
-
[Journal Article] Health-related quality of life after carbon-ion radiotherapy for prostate cancer: A 3-year prospective study.2014
Author(s)
Katoh H, Tsuji H, Ishikawa H, Kamada T, Wakatsuki M, Hirasawa N, Suzuki H, Akakura K, Nakano T, Shimazaki J, Tsujii H.
-
Journal Title
Int J Urol.
Volume: 21
Issue: 4
Pages: 370-5
DOI
Related Report
Peer Reviewed
-
[Journal Article] Loss of PTEN is associated with aggressive behavior in ERG positive prostate cancer2014
Author(s)
Leinonen KA, Saram臾i OR, Furusato B, Kimura T, Takahashi H, Egawa S, Suzuki H, Keiger K, Hahm SH, Isaacs WB, Tolonen TT, Stenman UH, Tammela TLJ, Nykter M, Bova GS, Visakorpi T
-
Journal Title
Cancer Epidemiol Biomarkers Prev
Volume: 印刷中
Issue: 12
Pages: 2333-2344
DOI
Related Report
Peer Reviewed
-
[Journal Article] Development of nomogram to non-steroidal antiandrogen sequential alternation in prostate cancer for predictive model.2014
Author(s)
Kamiya N, Suzuki H, Nishimura K, Fujii M, Okegawa T, Matsuda T, Morita T, Takihana Y, Ozono S, Namiki M, Matsubara A, Ichikawa T, Miki T.
-
Journal Title
Jpn J Clin Oncol.
Volume: 44
Issue: 3
Pages: 263-269
DOI
Related Report
Peer Reviewed
-
-
[Journal Article] Clinical outcomes by relative docetaxel dose and dose intensity as chemotherapy for Japanese patients with castration-resistant prostate cancer: a retrospective multi-institutional collaborative study.2013
Author(s)
Kamiya N, Suzuki H, Ueda T, Sato N, Nakatsu H, Mikami K, Sato N, Nomura K, Akakura K, Okano T, Ooki T, Naya Y, Ota S, Masai M, Ichikawa T.
-
Journal Title
Int J Clin Oncol.
Volume: 19
Issue: 1
Pages: 157-164
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
[Presentation] Assessment of Arterial Stiffness Using Cardio-Ankle Vascular Index in Patients with Prostate Cancer Treated by a Short-Term of Androgen Deprivation Therapy.2015
Author(s)
Oka R, Utumi T, Kamiya N, Lee F, Endo T, Yano M, Kamijima S, Nishimi D, Takanami M, Suzuki H
Organizer
SIU2015
Place of Presentation
Melbourne, Victoria, Australia
Year and Date
2015-10-16
Related Report
Int'l Joint Research
-
[Presentation] Transcriptionally-Targeted Retroviral Replicating Vectors: A Novel Strategy for Gene Therapy of Prostate Caner.2015
Author(s)
Kamijima S, Kimura T, Inagaki A, Hiraoka K, Haga K, Collins S, Hermann K, Kamiya N, Hacke K, Logg C, Kao C, Bochner B, Kasahara N, Suzuki H
Organizer
SIU2015
Place of Presentation
Melbourne, Victoria, Australia
Year and Date
2015-10-16
Related Report
Int'l Joint Research
-
-
[Presentation] Nadir Testosterone after Long-Term Follow-Up Predicts Prognosis of Prostate Cancer Patients Treated With Combined Androgen Blockade.2015
Author(s)
Shuhei Kamada, Shinichi Sakamoto, Keisuke Ando, Ayumi Muroi, Miki Fuse, Koji Kawamura, Takashi Imamoto, Hiroyoshi Suzuki, Maki Nagata, Naoki Nihei, Koichiro Akakura, Tomohiko Ichikawa
Organizer
America Urological Association Annual Meeting 2015
Place of Presentation
New Orleans, LA, USA
Year and Date
2015-05-19
Related Report
Int'l Joint Research
-
-
-
-
-
-
[Presentation] Validation of active surveillance criteria for pathological insignificant prostate cancer in Japanese men
Author(s)
Yamada Y, Sakamoto S, Sazuka T, Goto Y, Yanagisawa M, Kawamura K, Kamiya N, Imamoto T, Nihei N, Suzuki H, Sato N, Ichikawa T
Organizer
The 4th congress of Asian Pacific Prostate Society
Place of Presentation
沖縄県那覇市 万国津梁館
Related Report
-
[Presentation] Prodrug-activator gene therapy using prostate-targeted retroviral replicating vectors
Author(s)
Kamijima S, Kimura T, Haga K, Hiraoka K, Inagaki A, Tam Q, Logg CR, Kao C, Bochner BH, Suzuki H, Kasahara N, Ichikawa T
Organizer
The 4th congress of Asian Pacific Prostate Society
Place of Presentation
沖縄県那覇市 万国津梁館
Related Report
-
-
-
-